Pazopanib fails to show OS benefit for ovarian cancer
30 Oct 2019
byAudrey Abella
The oral multikinase VEGFR*1, 2, and 3 inhibitor pazopanib failed to improve overall survival (OS) in advanced ovarian cancer patients who have not progressed following first-line chemotherapy, according to the results of the AGO-OVAR16** study.